New antibody drug shows promise for tough kidney disease
NCT ID NCT05398653
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug, MIL62, in 94 adults with primary membranous nephropathy, a serious kidney condition. The goal was to see if MIL62 is safe and can help reduce protein in the urine better than the standard drug cyclosporine. Participants received either MIL62 or cyclosporine and were followed for up to 104 weeks to check for remission and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tackle a tough kidney disease?
- Can a smarter antibody outsmart a kidney disease that resists standard treatment?
- Can engineered immune cells tame autoimmune kidney disease?
- Can a pill calm the immune attack on kidneys?
- Can a gene-silencing drug calm overactive complement in kidney disease?
- New gel could outperform standard therapy for kidney disease